Sentiment-Signal
27,6
Bearisch
Composite Score (0–100)
Insider (25%)
49.9
1 Insider, 8,8M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Unternehmen & Branche
| Name | Mineralys Therapeutics, Inc. |
|---|---|
| Ticker | MLYS |
| CIK | 0001933414 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,70 Mrd. USD |
| Beta | 0,69 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -154,651,000 | -2.29 | 661,806,000 | 646,693,000 | |
| 2025-09-30 | 10-Q | -36,932,000 | -0.52 | 599,947,000 | 576,427,000 | |
| 2025-06-30 | 10-Q | -43,274,000 | -0.66 | 335,724,000 | 313,551,000 | |
| 2025-03-31 | 10-Q | -42,211,000 | -0.79 | 354,941,000 | 341,555,000 | |
| 2024-12-31 | 10-K | -177,810,000 | -3.66 | 205,903,000 | 191,257,000 | |
| 2024-09-30 | 10-Q | -56,342,000 | -1.13 | 268,253,000 | 236,932,000 | |
| 2024-06-30 | 10-Q | -41,014,000 | -0.83 | 318,492,000 | 290,095,000 | |
| 2024-03-31 | 10-Q | -31,508,000 | -0.70 | 347,249,000 | 328,045,000 | |
| 2023-12-31 | 10-K | -71,898,000 | -1.99 | 251,636,000 | 241,154,000 | |
| 2023-09-30 | 10-Q | -22,760,000 | -0.57 | 277,555,000 | 264,012,000 | |
| 2023-06-30 | 10-Q | -12,141,000 | -0.31 | 291,217,000 | 285,010,000 | |
| 2023-03-31 | 10-Q | -12,608,000 | -0.51 | 306,435,000 | 295,875,000 | |
| 2022-12-31 | 10-K | -29,799,000 | -5.77 | 114,442,000 | -52,269,000 | |
| 2022-09-30 | 10-Q | -6,678,000 | -1.29 | -43,414,000 | ||
| 2022-06-30 | 10-Q | -6,479,000 | -1.26 | -36,928,000 | ||
| 2022-03-31 | 10-Q | -7,569,000 | -1.48 | -30,475,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -416 | 31.33 | -13,033.28 | -0,8% | |
| 2026-04-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6,348 | 27.66 | -175,585.68 | -10,1% | |
| 2026-04-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -15,730 | 26.83 | -421,979.27 | -24,4% | |
| 2026-04-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -14,058 | 26.54 | -373,086.67 | -21,6% | |
| 2026-04-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2,170 | 27.38 | -59,414.60 | -3,4% | |
| 2026-03-31 | Karydas Daphne | Director | Open Market Sale | -3,000 | 25.00 | -75,000.00 | -4,3% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -453 | 27.05 | -12,254.15 | -0,7% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -19,364 | 25.50 | -493,793.62 | -28,5% | |
| 2026-03-31 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -55,183 | 26.54 | -1,464,474.05 | -84,6% | |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 58,300 | 24.16 | 1,408,528.00 | +81,4% | |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 310,700 | 23.67 | 7,354,269.00 | +424,8% | |
| 2026-03-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -417 | 25.65 | -10,696.05 | -0,6% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -10,726 | 25.91 | -277,922.46 | -16,1% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -253 | 27.82 | -7,038.46 | -0,4% | |
| 2026-03-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -3,079 | 27.37 | -84,264.53 | -4,9% | |
| 2026-03-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6,348 | 27.37 | -173,747.93 | -10,0% | |
| 2026-03-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2,171 | 26.84 | -58,269.64 | -3,4% | |
| 2026-02-17 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -417 | 27.59 | -11,505.03 | -0,7% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -3,541 | 27.33 | -96,775.53 | -5,6% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -4,166 | 27.33 | -113,856.78 | -6,6% | |
| 2026-02-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6,348 | 27.58 | -175,100.06 | -10,1% | |
| 2026-02-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -5,828 | 28.94 | -168,634.93 | -9,7% | |
| 2026-02-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -521 | 29.64 | -15,441.76 | -0,9% | |
| 2026-02-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2,171 | 30.21 | -65,585.91 | -3,8% | |
| 2026-01-20 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -416 | 32.10 | -13,353.60 | -0,8% | |
| 2026-01-14 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11,367 | 32.61 | -370,644.91 | -21,4% | |
| 2026-01-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -7,709 | 32.75 | -252,469.75 | -14,6% | |
| 2026-01-12 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -7,117 | 33.15 | -235,932.11 | -13,6% | |
| 2026-01-12 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -6,348 | 32.32 | -205,143.24 | -11,9% | |
| 2026-01-12 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -9,119 | 32.21 | -293,707.49 | -17,0% | |
| 2026-01-12 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -10,758 | 32.14 | -345,723.39 | -20,0% | |
| 2026-01-09 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2,170 | 33.27 | -72,195.90 | -4,2% | |
| 2026-01-05 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -53,470 | 35.53 | -1,899,553.83 | -109,7% | |
| 2026-01-05 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -139,245 | 34.83 | -4,849,555.24 | -280,1% | |
| 2026-01-02 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -70,037 | 35.87 | -2,511,919.03 | -145,1% | |
| 2025-11-20 | Slingsby Brian Taylor | Director, 10% Owner | Open Market Sale | -1,000,000 | 43.35 | -43,350,000.00 | -2504,2% | |
| 2025-11-13 | Karydas Daphne | Director | Open Market Sale | -10,115 | 45.81 | -463,350.95 | -26,8% | |
| 2025-11-13 | Gold Alexander M | Director | Open Market Sale | -12,742 | 46.50 | -592,503.00 | -34,2% | |
| 2025-11-13 | Karydas Daphne | Director | Open Market Sale | -4,885 | 46.36 | -226,446.13 | -13,1% | |
| 2025-11-12 | Gold Alexander M | Director | Open Market Sale | -1,933 | 47.28 | -91,385.67 | -5,3% | |
| 2025-11-12 | Gold Alexander M | Director | Open Market Sale | -5,000 | 46.50 | -232,500.00 | -13,4% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -29,207 | 45.20 | -1,320,165.16 | -76,3% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -1,015 | 42.00 | -42,630.00 | -2,5% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -1,561 | 42.68 | -66,622.54 | -3,8% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -4,142 | 43.50 | -180,183.21 | -10,4% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8,456 | 45.18 | -382,046.31 | -22,1% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8,485 | 42.34 | -359,258.29 | -20,8% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -11,295 | 41.87 | -472,931.82 | -27,3% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -12,952 | 41.65 | -539,479.29 | -31,2% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -32,718 | 46.88 | -1,533,976.89 | -88,6% | |
| 2025-11-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -38,900 | 45.93 | -1,786,587.53 | -103,2% | |
| 2025-11-11 | Gold Alexander M | Director | Open Market Sale | -5,000 | 47.08 | -235,408.00 | -13,6% | |
| 2025-11-11 | Gold Alexander M | Director | Open Market Sale | -10,000 | 42.43 | -424,298.00 | -24,5% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -4,000 | 43.50 | -173,983.60 | -10,1% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -8,862 | 42.31 | -374,946.79 | -21,7% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -12,806 | 41.64 | -533,235.44 | -30,8% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -32,850 | 46.89 | -1,540,211.67 | -89,0% | |
| 2025-11-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -112,275 | 45.83 | -5,145,956.21 | -297,3% | |
| 2025-10-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -10,369 | 43.01 | -445,982.10 | -25,8% | |
| 2025-10-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -13,548 | 42.63 | -577,544.47 | -33,4% | |
| 2025-10-13 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -1,552 | 43.03 | -66,782.40 | -3,9% | |
| 2025-10-13 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -7,366 | 41.90 | -308,650.87 | -17,8% | |
| 2025-10-13 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -3,392 | 42.26 | -143,332.69 | -8,3% | |
| 2025-09-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -2,065 | 36.47 | -75,320.46 | -4,4% | |
| 2025-09-15 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -9,302 | 35.90 | -333,945.52 | -19,3% | |
| 2025-09-04 | AKKARAJU SRINIVAS | Director | Open Market Purchase | 588,235 | 25.50 | 14,999,992.50 | +866,5% | |
| 2025-09-04 | RA CAPITAL MANAGEMENT, L.P. | Director | Open Market Purchase | 1,176,470 | 25.50 | 29,999,985.00 | +1733,0% | |
| 2025-08-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11,365 | 12.93 | -146,986.95 | -8,5% | |
| 2025-07-30 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -8,425 | 15.10 | -127,203.18 | -7,3% | |
| 2025-07-30 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -51,500 | 14.70 | -757,168.45 | -43,7% | |
| 2025-07-29 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -807 | 14.00 | -11,301.87 | -0,7% | |
| 2025-07-28 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -12,946 | 14.04 | -181,803.27 | -10,5% | |
| 2025-07-14 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11,366 | 14.59 | -165,878.81 | -9,6% | |
| 2025-07-11 | Congleton Jon | Director, Officer, Chief Executive Officer | Open Market Sale | -15,884 | 14.51 | -230,430.78 | -13,3% | |
| 2025-07-11 | Levy Adam Scott | Officer, CFO and Secretary | Open Market Sale | -10,758 | 14.45 | -155,454.18 | -9,0% | |
| 2025-06-13 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11,366 | 14.60 | -165,931.10 | -9,6% | |
| 2025-05-14 | Rodman David Malcom | Officer, Chief Medical Officer | Open Market Sale | -11,366 | 15.29 | -173,773.64 | -10,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.